All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How do you treat AML that has evolved from MPD?

During the Acute Leukemia Forum 2021, the AML Hub spoke to Raajit K. Rampal, Memorial Sloan Kettering Cancer Center, New York, US. We asked, How do you treat AML that has evolved from myeloproliferative disorders (MPD)?

How do you treat AML that has evolved from MPD?

Historically, patients who evolve from MPD to AML tend to have the worst prognosis among all AML subtypes due to their genomic profile. In this video, Rampal discusses treatment approaches in this setting. He believes there is an unmet need in this population, so patients with post-MPD AML should be prioritized in clinical trials, where possible.


More about...